Evolus (NASDAQ:EOLS – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Earnings & Valuation
This table compares Evolus and ARS Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $316.49 million | 1.61 | -$51.64 million | ($0.52) | -14.87 |
| ARS Pharmaceuticals | $84.28 million | 4.99 | -$171.30 million | ($2.18) | -1.94 |
Insider & Institutional Ownership
90.7% of Evolus shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Evolus and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -10.85% | N/A | -13.00% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Analyst Recommendations
This is a summary of recent ratings for Evolus and ARS Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
Evolus presently has a consensus target price of $14.50, suggesting a potential upside of 87.58%. ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 491.02%. Given ARS Pharmaceuticals’ higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Evolus.
Volatility and Risk
Evolus has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Summary
Evolus beats ARS Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
